Cargando…

No increase of serum neurofilament light in relapsing-remitting multiple sclerosis patients switching from standard to extended-interval dosing of natalizumab

BACKGROUND: Accumulating evidence supports the efficacy of administering natalizumab (NZ) with extended-interval dosing (EID) in patients with relapsing-remitting multiple sclerosis (RRMS). OBJECTIVES: We switched NZ dosing from 4-week to 6-week intervals in patients with RRMS, and investigated the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Johnsson, Magnus, Farman, Helen H, Blennow, Kaj, Zetterberg, Henrik, Malmeström, Clas, Axelsson, Markus, Lycke, Jan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2022
Materias:	Original Research Papers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9574231/ https://www.ncbi.nlm.nih.gov/pubmed/35856574 http://dx.doi.org/10.1177/13524585221108080

Ejemplares similares

Intrathecal kappa free light chain synthesis is associated with worse prognosis in relapsing–remitting multiple sclerosis
por: Rosenstein, Igal, et al.
Publicado: (2023)

Increased intrathecal neurofilament light and immunoglobulin M predict severe disability in relapsing-remitting multiple sclerosis
por: Rosenstein, Igal, et al.
Publicado: (2022)

Monitoring disease activity in multiple sclerosis using serum neurofilament light protein
por: Novakova, Lenka, et al.
Publicado: (2017)

High levels of kappa free light chain synthesis predict cognitive decline in relapsing-remitting multiple sclerosis
por: Rosenstein, Igal, et al.
Publicado: (2023)

Extended Interval Dosing Natalizumab and impact on neuropsychological deficits in Relapsing-Remitting Multiple Sclerosis
por: McManus, Eileen J., et al.
Publicado: (2022)

The role of autoimmune antibodies to predict secondary autoimmunity in patients with relapsing-remitting multiple sclerosis treated with alemtuzumab: A nationwide prospective survey
por: Sandgren, Sofia, et al.
Publicado: (2023)

Exploring CSF neurofilament light as a biomarker for MS in clinical practice; a retrospective registry-based study
por: Rosenstein, Igal, et al.
Publicado: (2021)

Cerebrospinal fluid growth-associated protein 43 in multiple sclerosis
por: Sandelius, Åsa, et al.
Publicado: (2019)

SARS‐COV‐2 a trigger of myelin oligodendrocyte glycoprotein‐associated disorder
por: Johnsson, Magnus, et al.
Publicado: (2022)

Autologous haematopoietic stem cell transplantation compared with alemtuzumab for relapsing–remitting multiple sclerosis: an observational study
por: Zhukovsky, Christina, et al.
Publicado: (2021)

Serum glial fibrillary acidic protein in natalizumab-treated relapsing-remitting multiple sclerosis: An alternative to neurofilament light
por: Wessels, Mark HJ, et al.
Publicado: (2023)

A five-year observational prospective mono-center study of the efficacy of alemtuzumab in a real-world cohort of patients with multiple sclerosis
por: Sandgren, Sofia, et al.
Publicado: (2023)

Neurofilament-light and contactin-1 association with long-term brain atrophy in natalizumab-treated relapsing-remitting multiple sclerosis
por: van Lierop, Zoë YGJ, et al.
Publicado: (2022)

Searching for neurodegeneration in multiple sclerosis at clinical onset: Diagnostic value of biomarkers
por: Novakova, Lenka, et al.
Publicado: (2018)

High Interferon-γ Uniquely in Vδ1 T Cells Correlates with Markers of Inflammation and Axonal Damage in Early Multiple Sclerosis
por: Singh, Avadhesh Kumar, et al.
Publicado: (2017)

Natalizumab: A new treatment for relapsing remitting multiple sclerosis
por: Hutchinson, Michael
Publicado: (2007)

Natalizumab is Effective for the Treatment of Relapsing-remitting Tumefactive Multiple Sclerosis
por: Nakamura, Masataka, et al.
Publicado: (2017)

Cost-effectiveness analysis of escalating to natalizumab or switching among immunomodulators in relapsing-remitting multiple sclerosis in Italy
por: Furneri, Gianluca, et al.
Publicado: (2019)

CSF orexin-A levels after rituximab treatment in recent onset narcolepsy type 1
por: Wasling, Pontus, et al.
Publicado: (2019)

Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease
por: Mattsson, Niklas, et al.
Publicado: (2017)

Use of Natalizumab in Patients with Active Relapsing-Remitting Multiple Sclerosis in Kuwait
por: Alroughani, R., et al.
Publicado: (2013)

Neurofilament light and tau as blood biomarkers for sports-related concussion
por: Shahim, Pashtun, et al.
Publicado: (2018)

Pharmacodynamics of natalizumab extended interval dosing in MS
por: Zhovtis Ryerson, Lana, et al.
Publicado: (2020)

Plasma concentration of neurofilament light chain protein decreases after switching from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate
por: Hermansson, Linn, et al.
Publicado: (2019)

A randomized study of natalizumab dosing regimens for relapsing–remitting multiple sclerosis
por: Trojano, Maria, et al.
Publicado: (2021)

Increased CSF Levels of Phosphorylated Neurofilament Heavy Protein following Bout in Amateur Boxers
por: Neselius, Sanna, et al.
Publicado: (2013)

Long-term evaluation of NEDA-3 status in relapsing-remitting multiple sclerosis patients after switching from natalizumab to fingolimod
por: Diem, Lara, et al.
Publicado: (2018)

Neurofilament light chain predicts disease activity in relapsing-remitting MS
por: Varhaug, Kristin N., et al.
Publicado: (2017)

No change in plasma tau and serum neurofilament light concentrations in adolescent athletes following sport-related concussion
por: Wallace, Colin, et al.
Publicado: (2018)

Treatment with Natalizumab in Relapsing–Remitting Multiple Sclerosis Patients Induces Changes in Inflammatory Mechanism
por: Ramos-Cejudo, Jaime, et al.
Publicado: (2011)

Bruising following natalizumab infusion for relapsing-remitting multiple sclerosis: a case report
por: Gatzonis, Stylianos, et al.
Publicado: (2009)

Impact of Natalizumab on Ambulatory Improvement in Secondary Progressive and Disabled Relapsing-Remitting Multiple Sclerosis
por: Cadavid, Diego, et al.
Publicado: (2013)

Impact of Natalizumab Treatment on Fatigue, Mood, and Aspects of Cognition in Relapsing–Remitting Multiple Sclerosis
por: Kunkel, Annett, et al.
Publicado: (2015)

Cost-effectiveness analysis of rituximab versus natalizumab in patients with relapsing remitting multiple sclerosis
por: Rezaee, Mehdi, et al.
Publicado: (2022)

Ocrelizumab after natalizumab in JC-virus positive relapsing remitting multiple sclerosis patients
por: van Lierop, ZYGJ, et al.
Publicado: (2021)

Cerebrospinal fluid levels of glial marker YKL-40 strongly associated with axonal injury in HIV infection
por: Hermansson, Linn, et al.
Publicado: (2019)

Blood neurofilament light in remote settings: Alternative protocols to support sample collection in challenging pre‐analytical conditions
por: Simrén, Joel, et al.
Publicado: (2021)

Neurofilament levels, disease activity and brain volume during follow-up in multiple sclerosis
por: Håkansson, Irene, et al.
Publicado: (2018)

MicroRNA regulate immune pathways in T-cells in multiple sclerosis (MS)
por: Jernås, Margareta, et al.
Publicado: (2013)

Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis
por: Kuhle, Jens, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_cuvrpulckcu6l1fh5db56rl2be